Evidence map›Paper›PMID 40131900›Full record

ArticlePloS one2025

The effect of antibiotic prescription in non-critically ill hospitalized patients with COVID-19: A Japanese inpatient database study.

Haruka Imai, Jun Suzuki, Tomoki Mizuno, Shota Takahashi, Hideya Itagaki, Makiko Yoshida, Shiro Endo, Eiichi N Kodama

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Haruka ImaiDepartment of Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan.
Jun SuzukiDivision of Infectious Diseases, Tohoku Medical and Pharmaceutical University Hospital, Miyagi, Japan.
Tomoki MizunoDivision of Infectious Diseases, Tohoku Medical and Pharmaceutical University Hospital, Miyagi, Japan.
Shota TakahashiDepartment of Infection Prevention and Control, Tohoku Medical and Pharmaceutical University Hospital, Miyagi, Japan.
Hideya ItagakiDivision of Infectious Diseases and Infection Control, Department of Social and Community Medicine, Graduate School of Medicine, Tohoku Medical and Pharmaceutical University, Miyagi, Japan.
Makiko YoshidaDivision of Infectious Diseases, Tohoku Medical and Pharmaceutical University Hospital, Miyagi, Japan.
Shiro EndoDivision of Infectious Diseases, Tohoku Medical and Pharmaceutical University Hospital, Miyagi, Japan.
Eiichi N KodamaDepartment of Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan.ORCID https://orcid.org/0000-0002-6622-2752

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCoronavirus disease 2019 (COVID-19) is an ongoing global pandemic. Bacterial coinfections with COVID-19 occur in 3.5% of COVID-19 cases, with a higher incidence in severe cases. Although antibiotics have been prescribed to treat non-critically ill patients with COVID-19, their effect on non-critically ill hospitalized patients with COVID-19 remains uncertain.

methodsWe analyzed data from non-critically ill hospitalized patients with COVID-19 who were older than 18 years between January 1, 2020, and May 31, 2023. We performed propensity score matching analysis, evaluating in-hospital mortality with or without antibiotic prescription within 2 days of admission. Sensitivity analyses using inverse probability weighting and generalized estimating equation were also performed.

resultsEligible patients (n =  144,110) were divided into antibiotic prescription (n =  3,873) and control (n =  140,237) groups. One-to-one propensity score matching identified 3,861 pairs of patients who received antibiotic prescriptions within 2 days of admission. Following this, antibiotic prescription was associated with a decreased 28-day mortality rate (2.3% vs. 3.6%) and in-hospital mortality rate (4.0% vs. 5.0%) compared with the control group. Conversely, antibiotics increased Clostridioides difficile infection (CDI) compared with the control group (0.6% vs. 0.1%). No statistical differences were observed between both groups regarding acute kidney injury (0.4% vs. 0.2%). Sensitivity analysis showed similar outcomes.

conclusionsThis multicenter observational study in Japan showed that antibiotic prescriptions were associated with lower 28-day and in-hospital mortalities and an increased CDI risk in non-critically ill hospitalized patients with COVID-19.

Indexed as

Anti-Bacterial AgentsCOVID-19COVID-19 Drug TreatmentAdultAgedAged, 80 and overDatabases, FactualEast Asian PeopleFemaleHospitalizationHospital MortalityHumansInpatientsJapanMaleMiddle AgedAnti-Bacterial Agents

Identifiers

PMID40131900
PMCPMC11936251

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.